Glen Eagle Advisors, LLC Alkermes Plc. Transaction History
Glen Eagle Advisors, LLC
- $604 Billion
- Q1 2025
A detailed history of Glen Eagle Advisors, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 20 shares of ALKS stock, worth $598. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20
Previous 20
-0.0%
Holding current value
$598
Previous $575,000
14.78%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ALKS
# of Institutions
410Shares Held
177MCall Options Held
229KPut Options Held
436K-
Black Rock Inc. New York, NY29.1MShares$870 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$545 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.8MShares$352 Million0.05% of portfolio
-
State Street Corp Boston, MA8.02MShares$240 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.88MShares$206 Million3.72% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.91B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...